Kymera opens up $150M PIPE fi­nanc­ing, thanks to un­ex­pect­ed of­fer from in­vestors

A group of in­vestors — with the lead fund de­lib­er­ate­ly leav­ing its name out of the pub­lic view — just made an un­so­licit­ed fi­nanc­ing of­fer of $150 mil­lion to Kymera Ther­a­peu­tics, and it’s bound to raise a few eye­brows.

The pro­tein degra­da­tion biotech an­nounced ear­ly Fri­day that it was im­ple­ment­ing a PIPE fi­nanc­ing, sell­ing 2.7 mil­lion shares at $26 a share and then “pre-fund­ed war­rants” to buy 3 mil­lion more shares at just the slight­est bit un­der $26 a share.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER